Juvenescence Raises $100M To Advance Anti-Aging Programs

19 Aug 2019

• By Scrip Team

The financing, which brings the total raised by Juvenescence to $165m, comes as longevity R&D programs supported by the company move towards human testing.

Age_100 — Juvenescence backing longevity start-ups • Source: Shutterstock

Juvenescence Ltd. has raised $100m in a Series B financing round to fund its portfolio of anti-aging startups through to initial value inflection points.

UK-based Juvenescence, which was co-founded by biotech investor Jim Mellon, used the first $65m it raised to build out a...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Finance Watch: Vera Raises Debt, Taysha And Trevi Price Offering After Big Trial Wins

05 Jun 2025

• By Mandy Jackson

Public Company Edition: Public company funding in 2025 is down from 2024, but after recent positive data readouts Vera accessed up to $450m in new debt, while Taysha and Trevi grossed $200m and $100m, respectively, in stock offerings. Meanwhile, Keros, Stealth and others cut jobs.

Finance Watch: Is Six The Magic Number? May Sees Half Dozen VC Mega-Rounds

04 Jun 2025

• By Mandy Jackson

Private Company Edition: Six biopharma companies raised venture capital rounds totaling $100m or more in May, matching the number of mega-rounds in April and March. Among other recent financings, Syndeio launched with $90m and SpyGlass raised a $75m series D round.

Angelini Advances Brain Health Ambitions With GRIN Pact

27 May 2025

• By Kevin Grogan

The Italian drugmaker gets rights to Phase III-ready asset radiprodil.

GlycoEra’s Series B Cash Will Fund Efforts To Take On FcRn Inhibitor Class

27 May 2025

• By Joseph Haas

GlycoEra unveiled a $130m series B financing, saying the proceeds would enable it to take its first clinical candidate through proof-of-concept in autoimmune diseases.

A MoonLake Buyout Would Boost Merck & Co’s Immunology Ambitions

05 Jun 2025

• By Andrew McConaghie

As the patent protection clock ticks down on Merck’s flagship blockbuster Keytruda, the company is reported to be pursuing the inflammation and immunology biotech. Such a move would bulk up its sparse I&I pipeline.